Skip to main content
Supriya Lifescience Limited logo

Supriya Lifescience Limited — Investor Relations & Filings

Ticker · SUPRIYA ISIN · INE07RO01027 LEI · 894500RBVJX1EOJP0Y02 BSE.NS Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2024-05-21 Regulatory Filings
Country IN India
Listing BSE.NS SUPRIYA

About Supriya Lifescience Limited

https://www.supriyalifescience.com

Supriya Lifescience Limited is a research-driven manufacturer of Active Pharmaceutical Ingredients (APIs) with a focus on diverse therapeutic segments. The company specializes in the production of antihistamines, anti-allergics, vitamins, anesthetics, and anti-asthmatics. Its core product portfolio includes Chlorpheniramine Maleate, Ketamine Hydrochloride, and Salbutamol Sulphate, maintaining a significant global market share in these niche categories. Operating with a strong emphasis on backward integration, the firm ensures supply chain reliability and cost efficiency. The manufacturing infrastructure is compliant with international regulatory standards, including approvals from the USFDA, EDQM, and PMDA. Supriya Lifescience serves a broad international clientele across more than 100 countries, catering to both regulated and semi-regulated markets through its advanced R&D capabilities and commitment to quality excellence.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is an intimation letter dated May 21, 2024, informing stock exchanges and the public about an upcoming earnings call scheduled for May 29, 2024. It references the discussion of operational and financial performance for the fourth quarter and fiscal year ended March 31, 2024. The document includes details about the call, such as timing, management representatives, and dial-in numbers. It does not contain any actual financial data or results but serves as a notification of the earnings call event. According to the classification rules, such notifications are classified as Call Transcript (CT) only if they contain the full transcript of the call. Since this is only an announcement of the earnings call, it does not qualify as a transcript. It is also not an Earnings Release (ER) because it does not contain financial highlights or results. The best fitting category is Regulatory Filings (RNS) as a general regulatory announcement about the earnings call event.
2024-05-21 English
Board Meeting — SUPRIYA LIFESCIENCE LIMITED has informed the Exchange about Board Meeting to be held on 28-May-2024 to consider and approve the Yearly Audited Financial results of the Company for the…
Regulatory Filings
2024-05-20 English
Board Meeting — Financial Results/Dividend
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges informing them about an upcoming Board Meeting scheduled for May 28, 2024. The purpose of the meeting is to consider and approve the Audited Financial Results for the quarter and year ended March 31, 2024, and to recommend dividends. It also mentions the closure of the trading window in compliance with insider trading regulations. The document does not contain the financial results themselves but is an announcement of the meeting where such results will be approved and announced. The document length is short (2588 characters) and it serves as an intimation rather than the actual financial report. Therefore, it fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about a board meeting and upcoming financial results, not the report itself.
2024-05-20 English
Monitoring Agency Report
Regulatory Filings
2024-05-14 English
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification Classification · 95% confidence The document is a disclosure under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, stating that the promoter and promoter group have not made any encumbrance of shares during the financial year ended March 31, 2024. It is a regulatory compliance filing related to shareholding and encumbrance disclosures, not a financial report, earnings release, or management discussion. The document is short (2495 characters) and is a formal notification to stock exchanges. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes or status in significant share ownership levels or encumbrances. Therefore, the appropriate classification is MRQ with high confidence.
2024-05-02 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about scheduled meetings between company officials and analysts/institutional investors. It mentions that an Investor Presentation has been uploaded on the company's website and stock exchanges, but the document itself does not contain the presentation or detailed financial data. The document is primarily an announcement of the schedule and the availability of the presentation, not the presentation itself. The length is only 2340 characters, which is short and consistent with an announcement rather than a full report. Therefore, according to the MENU VS MEAL RULE, this document should be classified as an Investor Presentation announcement, but since there is no direct presentation content, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about investor meetings and presentation availability.
2024-04-25 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.